miRagen Therapeutics Initiates First Clinical Trial for MRG-106 in Lymphoma Patients. Brennan CaruthersMarch 2, 2016
Thrasos Announces Promising Results for Phase 2 THR-184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury (AKI). Brennan CaruthersFebruary 29, 2016
F-star Enters into Collaborative Discovery & Development Agreement with AbbVie for Bispecific Antibodies in Immuno-oncology. Brennan CaruthersJanuary 11, 2016
miRagen Therapeutics Secures $41 million Series C Financing to Advance Two MicroRNA Programs into Clinical Trials. Brennan CaruthersNovember 10, 2015
Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Studay for Acute Kidney Injury. Brennan CaruthersJuly 7, 2015
Thrasos Secures $21 Million to Complete Phase 2 Study of THR-184 in the Prevention of Acute Kidney Injury and Expand the Company's Renal Portfolio. Brennan CaruthersMarch 31, 2015
F-star Announces the Formation of Second Asset-Centric Vehicle, F-star Beta Ltd. Brennan CaruthersNovember 4, 2014
Bristol-Myers Squibb Enters into Agreement that Provides an Exclusive Option to Acquire F-star Alpha Ltd. and its Novel HER2-Targeted Therapy. Brennan CaruthersOctober 28, 2014
Thrasos Announces Successful Formal Interim Analysis and Clinical Update. Brennan CaruthersSeptember 16, 2014
Genocea Announces Positive Top-Line Phase 1 Results for Novel Universal Pneumococcus Vaccine Candidate GEN-004. Brennan CaruthersJune 23, 2014
F-star achieves milestone in collaboration with Boehringer Ingelheim. Brennan CaruthersJanuary 9, 2014
Genocea Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering. Brennan CaruthersDecember 23, 2013
Covagen and Tanabe Research Laboratories Expand Strategic Research Collaboration for Development of Bispecific FynomAbs. Brennan CaruthersDecember 6, 2013
Genocea Biosciences Initiates Phase 1 Study of Vaccine Candidate Gen-004 to Prevent Infections Caused by Pneumococcus. Brennan CaruthersDecember 5, 2013
F-star announces formation of new asset-centric vehicle, F-star Alpha Ltd, with €9.4m Series A investment. Brennan CaruthersOctober 23, 2013
Pronota Is To Receive Patent On Biomarker For Diagnosing Renal Failure In The US Despite Prometheus. Brennan CaruthersJune 6, 2013
International Consortium Awarded 6 Million Euro To Validate Pre-Eclampsia Early Detection Tests. Brennan CaruthersNovember 5, 2012
Genkyotex's NOX Inhibitor GKT137831 Phase I Data Presented at Kidney Week 2012. Brennan CaruthersNovember 2, 2012
Thrasos Secures $35 Million to Fund THR-184 Phase 2 Clinical Program for Treatment of Acute Kidney Injury. Brennan CaruthersOctober 25, 2012
